Cigna (CI) Stock Forecast & Price Target

Cigna Group is expected to have strong ongoing opportunity across its business, driven by its highly integrated, value-based approach and continued growth at Evernorth. Its recent wins of major contracts with the Department of Defense and Centene, paired with its lack of exposure to Medicare Advantage make it a solid investment choice with potential for growth and upside potential. However, investors should be cautious of the potential impact of factors such as biosimilar adoption, lack of specialty drug penetration, client losses or outmigration, and rising U.S. unemployment that could affect its growth in the near term.

Cigna Group is expected to experience a decrease in its earnings per share due to additional investments in its business, as well as potential legislative and regulatory changes in the healthcare industry. Despite its strong cash flow generation and diversified offerings, Cigna's current valuation is at a slight discount to its historical averages, and their focus on balancing debt reduction and share repurchases may limit near-term growth potential. Furthermore, Cigna's PBM business may face challenges in meeting government contracts and addressing public perception, leading to potential long-term risks for the company's growth and profitability.